The world of endocrinology never sleeps, and November 2025 was no exception! While it may have been a quieter month, it still delivered some intriguing developments that could shape the future of diabetes and related conditions. Here's a recap of the top 5 endocrinology headlines you might have missed:
The Battle for Diabetes Management:
Novo Nordisk's journey in November was a rollercoaster. Their drug amycretin, a once-weekly or daily treatment, showcased impressive weight loss and HbA1c reduction in type 2 diabetes (T2D) patients. This success sets the stage for a phase 3 program in 2026. But here's where it gets controversial: semaglutide, another Novo Nordisk drug, failed to significantly slow Alzheimer's progression, despite positive effects on related biomarkers. This led to the discontinuation of a planned extension study. However, the spotlight quickly shifted to tirzepatide, which demonstrated remarkable weight loss benefits in T1D patients, along with improved glycemic control and reduced HbA1c.
Expanding Horizons:
GLP-1 RAs are making their mark beyond diabetes. Semaglutide, in particular, has shown cardiorenal benefits in chronic kidney disease (CKD) patients, with or without diabetes. This finding emphasizes the need for broader applications of GLP-1 data in nephrology. Meanwhile, eloralintide, an amylin receptor agonist, outperformed placebo in weight management for obese adults with comorbidities, potentially due to its calorie intake-reducing effects.
Clinical Insights and Updates:
In the Diabetes Dialogue podcast, experts discussed Dexcom's new G7 sensor, offering a 15-day lifespan and seamless app integration. The episode also covered significant price drops for Ozempic and Wegovy, making these drugs more accessible. Additionally, the podcast delved into the Evoke trials, highlighting the complexities of Alzheimer's treatment and the potential of tirzepatide in T1D management.
And this is the part most people miss: these developments are not just about scientific breakthroughs; they're about improving patient lives. The success of amycretin and tirzepatide in weight loss and glycemic control could revolutionize diabetes management, offering new hope to millions. But with the mixed results of semaglutide, the question arises: are we overlooking potential benefits in other areas?
Stay tuned as the endocrinology field continues to evolve, and join the conversation: what do you think are the most promising avenues for diabetes research and treatment? Share your thoughts in the comments below!
